Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

This study is looking for women who are 18 years old or older. You might be able to take part if you have a confirmed diagnosis of certain types of womb cancer (specifically, epithelial endometrial carcinoma, including carcinosarcomas, but not other types like sarcomas).

Your cancer needs to be either newly diagnosed at an advanced stage (Stage III or IV) or it needs to be a recurrence, meaning it has come back after previous treatment and surgery alone isn't expected to be enough to cure it. You should not have received any previous treatment for this current cancer, unless it was a type of treatment given after surgery to prevent recurrence, and it's been at least 12 months since you finished that treatment.

There are also some things that would mean you can't join the study. For example, if you have certain other serious health problems, if you've had previous specific types of cancer treatment (like PARP inhibitors or certain immune therapies), or if your cancer has spread to your brain or spinal cord. The study team will review your full medical history to see if you're a good fit.

If you join this study, your journey will involve a few steps. First, you'll undergo an initial treatment period where you'll receive a combination of chemotherapy drugs (carboplatin and paclitaxel) along with a medication called durvalumab. This part of the treatment will likely involve regular visits to the hospital for infusions.

After this first phase, you'll move into the maintenance phase. During this time, you'll continue to receive durvalumab. You will also either receive a medication called olaparib or a placebo (a dummy pill that looks like olaparib but contains no active medicine). Which one you receive will be decided randomly, like flipping a coin. You won't know whether you're getting olaparib or the placebo.

You'll have regular appointments throughout the study for check-ups, scans, and blood tests to monitor your health, how the treatment is working, and to check for any side effects. The total duration of your participation will depend on how you respond to the treatment and the study's protocol, but it will involve continued follow-up even after active treatment has ended.